The insulin-like growth factor 1 receptor in cancer: old focus, new future

Eur J Cancer. 2007 Sep;43(13):1895-904. doi: 10.1016/j.ejca.2007.05.021. Epub 2007 Jul 10.


The importance of insulin-like growth factor 1 receptor (IGF-1R) signalling in malignant behaviour of tumour cells is well established. Currently, development of drugs targeting the IGF-1R as anticancer treatment is emerging. Several IGF-1R targeting strategies are being investigated in phases I and II clinical trials. Interactions of IGF-1R with insulin receptor, however, might complicate efficiency and tolerability of such drugs. This review describes mechanisms, recent developments and potential limitations of IGF-1R antibodies and tyrosine kinase inhibitors.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Forecasting
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Protein Kinase Inhibitors / therapeutic use
  • Receptor, IGF Type 1 / drug effects
  • Receptor, IGF Type 1 / metabolism*
  • Signal Transduction / drug effects


  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Receptor, IGF Type 1